MARKET

PRPH

PRPH

Prophase Labs Inc
NASDAQ
4.950
-0.110
-2.17%
Closed 16:00 04/25 EDT
OPEN
5.06
PREV CLOSE
5.06
HIGH
5.23
LOW
4.900
VOLUME
12.15K
TURNOVER
0
52 WEEK HIGH
9.94
52 WEEK LOW
4.050
MARKET CAP
89.32M
P/E (TTM)
-5.0754
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PRPH last week (0415-0419)?
Weekly Report · 3d ago
ProPhase Labs Shares Jump on New AI-Based Project
Shares of ProPhase Labs are up 17%, at $7.18, in late trading. The stock is now up 59% since the start of the year. The company unveiled a new project that uses an artificial-intelligence platform and its massive genomics database. ProPhase will use the project to identify new cancer therapeutics.
Dow Jones · 04/16 19:46
ProPhase Labs Unveils Project ZenQ-AI; Leveraging ProPhase Labs' AI Platform, Massive Genomics Database And Patented Esophageal Cancer Insights For Antibody Drug Conjugates Development
Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Project ZenQ-AI uses the Company's state-of-the-art AI platform to identify possible antibody drug conjugate candidates for new cancer therapies. The Company is harnessing its massive genomic database from whole genome sequencing.
Benzinga · 04/16 12:15
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
NASDAQ · 04/15 11:47
Weekly Report: what happened at PRPH last week (0408-0412)?
Weekly Report · 04/15 09:49
ProPhase Labs Seeks To Transform Esophageal Cancer Detection And Management With Launch Of Its BE-Smart Test In H2 2024
ProPhase Labs, Inc. Is aiming for commercial launch of its breakthrough BE-Smart test for esophageal cancer in the second half of 2024. The BE- smart test is a patent-protected method for identifying cancer markers. The test targets an initial market size of $7 billion to $14 billion. The Company is nearing completion of rigorous validation studies of the test.
Benzinga · 04/10 12:09
PROPHASE LABS INC - AIMING FOR COMMERCIAL LAUNCH OF BE-SMART TEST FOR ESOPHAGEAL CANCER IN SECOND HALF OF 2024
Reuters · 04/10 12:03
Weekly Report: what happened at PRPH last week (0401-0405)?
Weekly Report · 04/08 09:51
More
About PRPH
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.

Webull offers ProPhase Labs Inc stock information, including NASDAQ: PRPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRPH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRPH stock methods without spending real money on the virtual paper trading platform.